We’re delighted that Action Medical Research will be our charity of the year for 2019. Please watch this incredibly powerful video of the work they have been doing with Lily, who has a rare disease called BPAN.
We look forward to hearing more about Lily’s story at our Gala Dinner where her father Simon will address guests.
The BIA is the UK’s leading trade association for life sciences, and we have an award-winning policy and public affairs team. The work is varied, stimulating, and at times challenging. At the moment, we have two vacancies open in our policy and public affairs team; A Policy and Public Affairs Manager, and a Talent, People and Skills Manager.
A job description only tells part of the story, so we sat down with BIA Policy and Projects Manager, Dr. Martin Turner, and BIA Senior Policy and Public Affairs Executive, Eric Johnsson, to find out more about their roles and what working at the BIA is really like.
Oxford, UK, 14 January 2019 - Oxfordshire companies which are progressing valuable innovations can apply now for The Oxford Science Park Innovation Award, one of 2019's Oxfordshire Business Awards (OXBA). The Oxford Science Park, one of the UK's leading parks for science and technology companies, is pleased to be sponsoring the award for the fourth year.
JP Morgan saw key M&A activity, new approaches from key UK pharma, a buzz about cell and gene therapy and concerns about the ongoing impact of the US Government shutdown. I’ve written a short blog on my perspective here.
On Brexit, the vote tomorrow is a key watershed, but for our sector we expect ongoing detail from the government on no-deal contingencies. We will focus our analytical and briefing capability on providing members with actionable information, in what is a very uncertain political context.
Key M&As set a positive tone for JPM 2019, as the sector shrugged off US stock market setbacks at the end of 2018. First out of the blocks were GSK taking Tesaro in a £3.8bn deal (announced before the conference) and since ringing in the new year we’ve seen Takeda complete their acquisition of Shire, Bristol-Myers Squibb acquire Celgene in a record breaking £70bn deal and Eli Lilly purchase Loxo Oncology for £6.24bn. These large pharma deals show desire for a strategic pipeline and prove the inherent value of biotech as a driver of innovation. More than half of new drugs registered in the coming years are expected to be made by small companies which large players may then look to add to their portfolio. The outlook for M&As looks strong and venture are keen to put money to work knowing the
EVONETIX LTD today announced it has appointed Stephanie Brooking as Head of Product Management. Evonetix aims to utilise its innovative silicon chip approach to deliver a high-throughput solution for the synthesis and assembly of DNA molecules with high fidelity. Stephanie will help to define the Company’s strategy for market entry and longer-term product marketing for its novel gene synthesis products.
The BIA welcomes the announcement of Nicola Blackwood as new Parliamentary Under-Secretary of State for Health.
BIA CEO, Steve Bates OBE, said: “As a former health minister and former chair of the science and technology committee, and serving as a board member of Eagle Genomics, Nicola knows our sector well and is well-placed to hit the ground running. We had a strong relationship with Nicola when she was minister for health, and we look forward to working with her to ensure the UK stays a world-leader in the life sciences.”
As we launch into 2019 against a backdrop of political uncertainty, it is reassuring to know that there are some things you can rely on. One of those is our annual Gala Dinner, which for many years has been a key event in the life sciences sector calendar, where around seven hundred senior executives in the biotechnology sector come together to meet new people and catch up with old friends.